Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a novel class of biologic therapy to ...

Clarivate Plc  a leading global provider of transformative intelligence, in partnership with Healthcare Executive, published by the China Pharmaceutical Enterprises Association, today announced the ...

Clene (NASDAQ:CLNN – Free Report) had its price target cut by Canaccord Genuity Group from $86.00 to $83.00 in a research report released on Thursday morning,Benzinga reports. They currently have a ...

Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials ... completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for ...

ELAHERE is the first and only novel therapy approved in the European Union specifically for patients with folate receptor-alpha (FR?) positive, platinum-resistant ovarian cancerELAHERE represents the ...

JonesTrading analyst Debanjana Chatterjee has reiterated their bullish stance on NTLA stock, giving a Buy rating on November 13. Debanjana ...

Unexpected cardiovascular complications: Manipulating the neck can sometimes affect blood flow and lead to unexpected ...

Completed Enrollment of Dose Escalation Part of Phase 1 Clinical Trial of its Next-Generation Nectin-4 Targeting ADC (CRB-701 ...